

Liposomal intra-articular gel provides components for ultra-low friction in the synovial joint, thus improving clinical and functional outcomes of patients with osteoarthritis

Paweł Bąkowski, Wojciech Madej. 2024. <https://doi.org/10.1016/j.joca.2024.02.069>

OBJECTIVE

The objective of the study was to evaluate the clinical effectiveness and safety of Lipotris™, a novel liposomal composite gel administered intra-articularly in patients with mild to moderate knee osteoarthritis (OA).

STUDY DESIGN





- 50 patients with knee OA (Kellgren-Lawrence classification grade 2 or 3) were subjected to 3 intra-articular injections (with 1-week intervals) of Lipotris™.
- The clinical assessment consisted of patient reported outcome measures (VAS, WOMAC total) accompanied by functional tests (The Timed Up and Go Test, The 5 Times Sit to Stand Test, The 10-Meter Walk Test).
- The assessments were performed: at the baseline (prior to the first injection) and 1, 3, 6 months after the third injection.

RESULTS:

- Lipotris™ therapy provides a rapid and sustained effect on pain relief (VAS score) and functional improvement (WOMAC total score) in OA patients, starting as early as the second week and continuing at 1, 3, and 6 months after therapy.
- Therapy with Lipotris™ significantly improves patients' functional status by increasing flexor and extensor muscle strength.
- No adverse effects related to Lipotris™ therapy have been reported.

CONCLUSIONS

Our findings indicate that individuals with mild to moderate knee OA experienced positive outcomes with Lipotris™ treatment, including pain management, functional recovery, and restoration of muscle strength. These benefits were noted already at 2 weeks after start of the treatment and were consistently maintained throughout the entire observation period, up to 6 months.





Lipotris™ composite gel, is a new-generation tribosupplement, tailored for three intra-articular injections into the synovial joints affected by osteoarthritis in order to alleviate the symptoms of the disease.

Lipotris™ as a liposomal composite gel provides a synergistic action of liposomes and hyaluronic acid, which are able to further interact with cartilage surface protein – lubricin. This unique synergy creates a surface with exceptionally low friction.

As a result, Lipotris™ is identified as a complete new class of joint supplement able to actively affect joint motion quality. Therapy based on Lipotris™ tribosupplement provides an accelerated pain relief with a sustainable duration of clinical effect.



Global marketing

Implai Sp. z o.o.
Hutnicza 15 B
81-061 Gdynia, Poland, EU
☎ +48 58 727 06 06
✉ office@implai.com



implai.com

Legal manufacturer

Biovico Sp. z o.o.
Hutnicza 15 B
81-061 Gdynia, Poland, EU
☎ +48 58 660 44 88
✉ office@biovico.com



biovico.com